An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
Primary Purpose
Gastroesophageal Reflux Disease
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Torax Medical, Inc. LINX Reflux Management System
Sponsored by
About this trial
This is an interventional treatment trial for Gastroesophageal Reflux Disease focused on measuring GERD
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years, < 85 years, life expectancy > 3yrs.
- Documented history of GERD symptoms such as heartburn and/or regurgitation.
- On daily PPI treatment for at least 3-months.
- Responsive to PPI treatment.
- GERD symptoms, in absence of PPI therapy (minimum 10 days).
- Ambulatory Esophageal pH < 4 for ≥ 5% time or pH < 4 for ≥ 3% time in supine position.
- Patient is a surgical candidate.
- Patient is willing and able to cooperate with follow-up examinations.
- Patient has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes (HIPAA).
Exclusion Criteria:
- The procedure is an emergency procedure.
- Patient is currently being treated with another investigational drug or investigational device.
- Patient has had prior gastric or esophageal surgery.
- Patient has had any previous endoscopic intervention for GERD
- Patient has suspected or confirmed esophageal or gastric cancer.
- Patient has any size paraesophageal hiatal hernia or sliding hiatal hernia ≥3cm. (Investigator to identify and record type of hiatal hernia at the time of assessment (i.e. para-esophageal, sliding)).
- Patient's esophageal motility is less than 35 mmHg peristaltic amplitude on wet swallows or > 30% failed (non-propulsive) peristaltic sequences.
- Patient has esophagitis - Grade B, C, D (LA Classification).
- Patient has Barretts Esophagus.
- Patient has BMI > 35.
- Patient has symptoms of dysphagia or indications of dysphagia from barium esophagram.
- Patient has Scleroderma and/or Achalasia.
- Patient has an esophageal stricture or gross esophageal anatomic abnormalities (obstructive lesions, etc.).
- Patient has an electrical implant or metallic, abdominal implant(s).
- Patient cannot understand trial requirements or is unable to comply with follow-up schedule.
- Patient is pregnant or nursing, or plans to become pregnant.
- Patient has a psychiatric disorder.
Sites / Locations
- University of Southern California, Keck School of Medicine
- Chapman Medical Center
- Abbott Northwestern Hospital
- Policlinico San Donato
- Academisch Medisch Centrum (AMC)
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Implantable Device
Arm Description
Subjects who meet eligibility criteria are implanted with the Magnetic Esophageal Sphincter device (MES)
Outcomes
Primary Outcome Measures
To Evaluate the Incidence of All Adverse Events at Various Time Points.
To Monitor the Improvement of GERD Symptoms.
Percentage of participants with a 50% or more reduction in total GERD-HRQL score is indicative of a substantial improvement in GERD symptoms
Secondary Outcome Measures
Full Information
NCT ID
NCT01058070
First Posted
January 26, 2010
Last Updated
January 28, 2021
Sponsor
Torax Medical Incorporated
1. Study Identification
Unique Protocol Identification Number
NCT01058070
Brief Title
An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
Official Title
An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
February 2007 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
August 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Torax Medical Incorporated
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Magnetic Esophageal Sphincter implant is intended to reinforce Esophageal Sphincter function in the treatment of Gastroesophageal Reflux Disease (GERD)
Detailed Description
The purpose of this feasibility study is to collect preliminary performance and safety information and develop procedural optimization for the Torax Medical Inc. Magnetic Esophageal Sphincter device (MES) in reinforcement of Esophageal Sphincter function to treat Gastroesophageal Reflux Disease (GERD). The information from this study will be used to support the design and conduct of an expanded clinical trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux Disease
Keywords
GERD
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
44 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Implantable Device
Arm Type
Experimental
Arm Description
Subjects who meet eligibility criteria are implanted with the Magnetic Esophageal Sphincter device (MES)
Intervention Type
Device
Intervention Name(s)
Torax Medical, Inc. LINX Reflux Management System
Intervention Description
Implantable device, Magnetic Esophageal Sphincter
Primary Outcome Measure Information:
Title
To Evaluate the Incidence of All Adverse Events at Various Time Points.
Time Frame
5 years
Title
To Monitor the Improvement of GERD Symptoms.
Description
Percentage of participants with a 50% or more reduction in total GERD-HRQL score is indicative of a substantial improvement in GERD symptoms
Time Frame
5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years, < 85 years, life expectancy > 3yrs.
Documented history of GERD symptoms such as heartburn and/or regurgitation.
On daily PPI treatment for at least 3-months.
Responsive to PPI treatment.
GERD symptoms, in absence of PPI therapy (minimum 10 days).
Ambulatory Esophageal pH < 4 for ≥ 5% time or pH < 4 for ≥ 3% time in supine position.
Patient is a surgical candidate.
Patient is willing and able to cooperate with follow-up examinations.
Patient has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes (HIPAA).
Exclusion Criteria:
The procedure is an emergency procedure.
Patient is currently being treated with another investigational drug or investigational device.
Patient has had prior gastric or esophageal surgery.
Patient has had any previous endoscopic intervention for GERD
Patient has suspected or confirmed esophageal or gastric cancer.
Patient has any size paraesophageal hiatal hernia or sliding hiatal hernia ≥3cm. (Investigator to identify and record type of hiatal hernia at the time of assessment (i.e. para-esophageal, sliding)).
Patient's esophageal motility is less than 35 mmHg peristaltic amplitude on wet swallows or > 30% failed (non-propulsive) peristaltic sequences.
Patient has esophagitis - Grade B, C, D (LA Classification).
Patient has Barretts Esophagus.
Patient has BMI > 35.
Patient has symptoms of dysphagia or indications of dysphagia from barium esophagram.
Patient has Scleroderma and/or Achalasia.
Patient has an esophageal stricture or gross esophageal anatomic abnormalities (obstructive lesions, etc.).
Patient has an electrical implant or metallic, abdominal implant(s).
Patient cannot understand trial requirements or is unable to comply with follow-up schedule.
Patient is pregnant or nursing, or plans to become pregnant.
Patient has a psychiatric disorder.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Ganz, MD
Organizational Affiliation
Minnesota Gastroenterolgy, PA
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Southern California, Keck School of Medicine
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
Chapman Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92869
Country
United States
Facility Name
Abbott Northwestern Hospital
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55407
Country
United States
Facility Name
Policlinico San Donato
City
Milano
ZIP/Postal Code
20097
Country
Italy
Facility Name
Academisch Medisch Centrum (AMC)
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
18846406
Citation
Bonavina L, Saino GI, Bona D, Lipham J, Ganz RA, Dunn D, DeMeester T. Magnetic augmentation of the lower esophageal sphincter: results of a feasibility clinical trial. J Gastrointest Surg. 2008 Dec;12(12):2133-40. doi: 10.1007/s11605-008-0698-1. Epub 2008 Oct 10.
Results Reference
background
PubMed Identifier
21037442
Citation
Bonavina L, DeMeester T, Fockens P, Dunn D, Saino G, Bona D, Lipham J, Bemelman W, Ganz RA. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. Ann Surg. 2010 Nov;252(5):857-62. doi: 10.1097/SLA.0b013e3181fd879b.
Results Reference
background
PubMed Identifier
22538694
Citation
Lipham JC, DeMeester TR, Ganz RA, Bonavina L, Saino G, Dunn DH, Fockens P, Bemelman W. The LINX(R) reflux management system: confirmed safety and efficacy now at 4 years. Surg Endosc. 2012 Oct;26(10):2944-9. doi: 10.1007/s00464-012-2289-1. Epub 2012 Apr 27.
Results Reference
background
PubMed Identifier
26437027
Citation
Saino G, Bonavina L, Lipham JC, Dunn D, Ganz RA. Magnetic Sphincter Augmentation for Gastroesophageal Reflux at 5 Years: Final Results of a Pilot Study Show Long-Term Acid Reduction and Symptom Improvement. J Laparoendosc Adv Surg Tech A. 2015 Oct;25(10):787-92. doi: 10.1089/lap.2015.0394. Epub 2015 Oct 5.
Results Reference
background
Learn more about this trial
An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
We'll reach out to this number within 24 hrs